Geovax Labs, INC. (GOVX) — SEC Filings

Overview

Geovax Labs, INC. (GOVX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 20, 2026: GeoVax Labs, Inc. filed an EFFECT form on April 20, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999999995-26-001237, was accepted at 00:15:21. The effectiveness date is listed as April 17, 2026.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 10 bearish, 39 neutral, 1 mixed. The dominant filing sentiment for Geovax Labs, INC. is neutral.

Filing Type Overview

Geovax Labs, INC. (GOVX) has filed 5 EFFECT, 29 8-K, 5 S-1, 6 10-Q, 2 DEF 14A, 1 S-1/A, 1 10-K, 1 SC 13G/A with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• GeoVax Labs EFFECT Filing Accepted — EFFECT · Apr 20, 2026 Risk: low
  GeoVax Labs, Inc. filed an EFFECT form on April 20, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 999999999
• GeoVax Labs Filing Becomes Effective — EFFECT · Apr 20, 2026 Risk: low
  GeoVax Labs, Inc. filed an EFFECT form on April 20, 2026, indicating the effectiveness of a filing related to Act 33, File No. 333-281973. The effectiveness dat
• EFFECT Filing — EFFECT · Apr 20, 2026
• GeoVax Labs SEC Filing Effectiveness Notice — EFFECT · Apr 20, 2026 Risk: low
  GeoVax Labs, Inc. filed an EFFECT form on April 20, 2026, indicating the effectiveness of a filing related to Act 33, File No. 333-281310. The company's busines
• GeoVax Labs Filing Becomes Effective — EFFECT · Apr 20, 2026 Risk: low
  GeoVax Labs, Inc. filed an EFFECT form on April 20, 2026, indicating the effectiveness of a filing related to Act 33, File No. 333-280040. The effectiveness dat
• GeoVax Labs Enters Material Definitive Agreement — 8-K · Dec 22, 2025 Risk: medium
  On December 19, 2025, GeoVax Labs, Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statement
• GeoVax Launches $0.41 Unit Offering Amidst Going Concern Warning — S-1 · Dec 12, 2025 Risk: high
  GeoVax Labs, Inc. (GOVX) is conducting a best efforts public offering of 18,292,683 Common Units at an assumed price of $0.41 per Unit, each consisting of one s
• 8-K Filing — 8-K · Nov 26, 2025
• GeoVax's Cash Dwindles Amidst Rising Losses, Government Revenue Plummets — 10-Q · Nov 13, 2025 Risk: high
  GeoVax Labs, Inc. reported a net loss of $6,318,914 for the three months ended September 30, 2025, an increase from a net loss of $5,815,468 for the same period
• GeoVax Faces 'Going Concern' Amidst Deep Losses, Seeks Funding for Pipeline — S-1 · Oct 17, 2025 Risk: high
  GeoVax Labs, Inc. (GOVX), a clinical-stage biotechnology company, is facing significant financial challenges, evidenced by a net loss of approximately $10.7 mil
• GeoVax Seeks Shareholder Nod for Warrant Exercise, Reverse Split — DEF 14A · Oct 14, 2025 Risk: high
  GeoVax Labs, Inc. (GOVX) is seeking stockholder approval for two critical proposals at a Special Meeting on November 26, 2025. The first proposal is to approve
• GeoVax Labs Files 8-K: Agreements, Equity Sales, and Financials — 8-K · Sep 30, 2025 Risk: medium
  On September 30, 2025, GeoVax Labs, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, reported un
• GeoVax Labs Faces Listing Rule Issues — 8-K · Aug 1, 2025 Risk: high
  GeoVax Labs, Inc. filed an 8-K on August 1, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and also filed fin
• GeoVax Labs Files 8-K on Financials — 8-K · Jul 29, 2025 Risk: low
  On July 28, 2025, GeoVax Labs, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and ex
• GeoVax Raises $1M in July Offering Amidst Zero Revenue — 10-Q · Jul 28, 2025 Risk: high
  GeoVax Labs, Inc. reported no revenue for the six months ended June 30, 2025, consistent with the prior year period. The company's net loss for the six months e
• GeoVax Labs Files 8-K with Material Agreement — 8-K · Jul 2, 2025 Risk: medium
  On July 1, 2025, GeoVax Labs, Inc. entered into a material definitive agreement. The company also provided a Regulation FD disclosure and filed financial statem
• GeoVax Q1 Loss Widens to $2.5M Amid Grant Decline, Offering Boosts Capital — S-1/A · Jun 26, 2025 Risk: high
  GeoVax Labs, Inc. (GOVX) reported a net loss of $2.5 million for Q1 2025, a significant increase from the $1.9 million net loss in Q1 2024, primarily due to inc
• GeoVax Seeks $25M Via ATM, Registers Warrants for Future Funding — S-1 · Jun 16, 2025 Risk: high
  GeoVax Labs, Inc. (GOVX) filed an S-1 to register 10,000,000 shares of common stock and 15,000,000 shares of common stock underlying warrants, along with 10,000
• GeoVax Labs Files 8-K on Security Holder Vote Matters — 8-K · Jun 5, 2025 Risk: low
  GeoVax Labs, Inc. filed an 8-K on June 5, 2025, reporting on a submission of matters to a vote of security holders. The filing does not contain specific details
• GeoVax Labs Files Q1 2025 10-Q — 10-Q · May 1, 2025 Risk: medium
  GeoVax Labs, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates, including information r
• GeoVax Labs Terminates Material Agreement — 8-K · Apr 14, 2025 Risk: medium
  GeoVax Labs, Inc. filed an 8-K on April 14, 2025, to report the termination of a material definitive agreement. The filing date indicates the event occurred on
• GeoVax Labs Files 8-K on Financials — 8-K · Mar 28, 2025 Risk: low
  GeoVax Labs, Inc. filed an 8-K on March 28, 2025, reporting on its Results of Operations and Financial Condition as of March 27, 2025. The filing includes finan
• GeoVax Labs Files 2024 10-K, Details March 2025 Warrant Offering — 10-K · Mar 27, 2025 Risk: medium
  GeoVax Labs, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, based in Smyrna, GA, reported on its operations in the pharmaceutica
• GeoVax Labs Files 8-K: Material Agreement, FD Disclosure — 8-K · Mar 25, 2025 Risk: medium
  On March 23, 2025, GeoVax Labs, Inc. entered into a Material Definitive Agreement. The company also provided a Regulation FD Disclosure and filed financial stat
• GeoVax Labs Files 8-K on Shareholder Vote Matters — 8-K · Jan 22, 2025 Risk: medium
  On January 22, 2025, GeoVax Labs, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify the
• GeoVax Labs Files 8-K: Corporate Details Updated — 8-K · Dec 18, 2024 Risk: low
  GeoVax Labs, Inc. filed an 8-K on December 18, 2024, reporting an event under 'Other Events'. The filing details the company's incorporation in Delaware, its IR
• GeoVax Labs Faces Delisting Notice — 8-K · Nov 18, 2024 Risk: high
  GeoVax Labs, Inc. filed an 8-K on November 18, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• GeoVax Labs Files 8-K on Financials and Operations — 8-K · Nov 13, 2024 Risk: medium
  GeoVax Labs, Inc. filed an 8-K on November 13, 2024, reporting on its financial condition and other events. The filing includes information on results of operat
• GeoVax Labs Files Q3 2024 10-Q, Details ATM Program & BARDA Contract — 10-Q · Nov 12, 2024 Risk: medium
  GeoVax Labs, Inc. filed its Q3 2024 10-Q report on November 12, 2024, covering the period ending September 30, 2024. The company is involved in the pharmaceutic
• GeoVax Labs Files 8-K Report — 8-K · Oct 16, 2024 Risk: medium
  On October 16, 2024, GeoVax Labs, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, but
• GeoVax Labs Files 8-K: Corporate Updates — 8-K · Oct 15, 2024 Risk: low
  GeoVax Labs, Inc. filed an 8-K on October 15, 2024, reporting other events and financial statements. The filing details the company's incorporation in Delaware,
• GeoVax Labs Files 8-K Report — 8-K · Oct 1, 2024 Risk: low
  On October 1, 2024, GeoVax Labs, Inc. filed an 8-K report detailing an "Other Event." The filing does not specify the exact nature of this event but is a standa
• GeoVax Labs Files Material Definitive Agreement 8-K — 8-K · Sep 25, 2024 Risk: medium
  On September 25, 2024, GeoVax Labs, Inc. filed an 8-K report detailing a material definitive agreement. The filing does not specify the other party involved in
• GeoVax Labs Files 8-K: Corporate Updates — 8-K · Sep 17, 2024 Risk: low
  GeoVax Labs, Inc. filed an 8-K on September 17, 2024, reporting other events and financial statements. The filing details the company's corporate structure, inc
• GeoVax Labs Files S-1 Amidst Corporate Changes — S-1 · Sep 6, 2024 Risk: medium
  GeoVax Labs, Inc. filed an S-1 form on September 6, 2024, detailing its financial status and future plans. The company, incorporated in Delaware, is in the phar
• GeoVax Labs Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 30, 2024 Risk: medium
  GeoVax Labs, Inc. entered into a material definitive agreement on August 28, 2024, related to unregistered sales of equity securities. The company also disclose
• GeoVax Labs Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 21, 2024 Risk: medium
  GeoVax Labs, Inc. announced on August 20, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity se
• GeoVax Labs Files 8-K on Financials — 8-K · Aug 7, 2024 Risk: medium
  On August 6, 2024, GeoVax Labs, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements a
• GeoVax Labs Q2 2024: Financing Activities Highlighted — 10-Q · Aug 6, 2024 Risk: medium
  GeoVax Labs, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities. Key events disc
• GeoVax Labs Files Proxy Statement for Sept. 17 Shareholder Meeting — DEF 14A · Aug 1, 2024 Risk: medium
  GeoVax Labs, Inc. filed a definitive proxy statement (DEF 14A) on August 1, 2024, for its annual meeting of stockholders scheduled for September 17, 2024. The f
• GeoVax Labs Files 8-K: Material Agreement & Equity Sale — 8-K · Jul 12, 2024 Risk: medium
  On July 11, 2024, GeoVax Labs, Inc. entered into a material definitive agreement related to the unregistered sale of equity securities. The company also made a
• GeoVax Labs Faces Delisting Concerns — 8-K · Jun 21, 2024 Risk: high
  GeoVax Labs, Inc. filed an 8-K on June 21, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indicates potential
• GeoVax Labs Enters Material Definitive Agreement — 8-K · Jun 18, 2024 Risk: medium
  On June 12, 2024, GeoVax Labs, Inc. entered into a Material Definitive Agreement. The company, incorporated in Delaware with its principal office in Smyrna, GA,
• GeoVax Labs Files S-1 with SEC — S-1 · Jun 7, 2024 Risk: medium
  GeoVax Labs, Inc. filed an S-1 form on June 7, 2024, detailing its financial status and business operations. The company, previously known as Dauphin Technology
• GeoVax Labs Faces Delisting Concerns — 8-K · May 24, 2024 Risk: high
  GeoVax Labs, Inc. filed an 8-K on May 24, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in Smyrna,
• GeoVax Labs Files 8-K on Corporate Matters — 8-K · May 23, 2024 Risk: low
  GeoVax Labs, Inc. filed an 8-K on May 23, 2024, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote of security
• GeoVax Labs Files 8-K: Equity Sales and Agreements — 8-K · May 21, 2024 Risk: medium
  On May 16, 2024, GeoVax Labs, Inc. entered into a material definitive agreement related to the sale of its common stock and warrants. The company also disclosed
• GeoVax Labs Files 8-K on Financials — 8-K · May 15, 2024 Risk: low
  GeoVax Labs, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition as of May 14, 2024. The filing includes financial
• GeoVax Labs, Inc. Files 10-Q for Q1 2024 — 10-Q · May 14, 2024 Risk: low
  GeoVax Labs, Inc. (GOVX) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. GeoVax Labs, Inc. filed a 10-Q for the period ending March 31, 2024. The

Frequently Asked Questions